This innovative approach, involving a bispecific complement engager (BiCE) that combines a Nb recruiting the complement-initiating protein C1q with single-chain variable fragments of broadly neutralizing antibodies targeting the HIV-1 envelope protein (Figure 1C), not only shows great potential for addressing HIV infection therapeutically but also paves the way for combatting other infectious diseases through complement-mediated killing of infected cells. This evidence concerns the gene ERVW-1 and HIV infectious disease.